Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Berkeley, Barratt Redrow, ITM Power

(Sharecast News) - Morgan Stanley downgraded Berkeley Group and Barratt Redrow on Tuesday and cut price targets across the board, as it took a more cautious stance on housebuilders - pointing to rising macro risks, fading rate support and the re-emergence of cost uncertainty. "Valuations are cheap, but catalysts are scarce," it said. "Absent clearer rate support, demand visibility is limited and we reset estimates lower, despite depressed sector valuations."

Morgan Stanley downgraded Berkeley to 'underweight' from 'equalweight' and slashed its price target on the stock to 2,990p from 3,840p as it noted the firm has cut profit forecasts, paused land acquisition and prioritised balance sheet strength over growth amid weak London and South East demand. The bank said its 2027 pre-tax profit estimate sits 6% below consensus.

Morgan Stanley also downgraded Barratt Redrow to 'equalweight' from 'overweight' and cut the price target to 300p from 430p, stating that while scale and a multi-brand platform offer strategic flexibility, the ability to fully realise revenue synergies was constrained in a weak demand environment, leaving performance increasingly macro-driven.

Analysts at Berenberg nudged up their target price on ITM Power from 100p to 110p on Tuesday after the hydrogen economy company secured roughly £86.5m of UK government funding, through an equity investment of £40m by Great British Energy and a potential grant from the UK Department for Energy Security and Net Zero of £46.5m.

Berenberg, which has a 'buy' rating on the stock, said the proceeds would support ITM Power's establishment of a new large-scale automated manufacturing line in the UK, with an annual capacity of one gigawatt for the firm's next-generation Chronos electrolyser stack.

"We think that the investment is a compelling endorsement of ITM's technology, as well as a clear demonstration of the UK government's commitment to promoting UK manufacturing capability in the sector, helping to underpin the country's ambitious hydrogen targets as part of its hydrogen allocation round funding programmes," said Berenberg. "In our view, this boost to its production capacity, alongside the launch and development of Chronos, is set to be a gamechanger for ITM and a strong platform for further growth."

Berenberg updated its numbers to incorporate the cash investments and expected capex from the new manufacturing line, with the German bank leaving its near-term revenue and underlying earnings numbers unchanged, but highlighting "the significant platform" the investment provides.

Share this article

Related Sharecast Articles

Broker tips: Anglo American, On The Beach
(Sharecast News) - Jefferies reiterated its 'buy' rating on Anglo American on Tuesday after the miner announced an agreement to sell its portfolio of steelmaking coal mines in Australia to private UK mining company Dhilmar for up to $3.9bn in cash.
Broker tips: AstraZeneca, GSK, Oxford Instruments
(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.
Broker tips: Aegon, Standard Life, Aberdeen, Card Factory
(Sharecast News) - JPMorgan reiterated its 'overweight' stance on Aegon on Friday and double-upgraded Standard Life as it said the sale of Aegon UK to Standard Life is highly likely to receive regulatory approval, which would be "very positive for both".
Broker tips: HSBC, Vistry
(Sharecast News) - Analysts at RBC Capital Markets raised their target price on banking giant HSBC from 1,200p to 1,275p on Thursday following the group's first quarter results a day earlier.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.